Hire a Pro: Compare Financial Advisors in Your Area
Finding the right financial advisor to fit your needs doesn't have to be hard. SmartAsset's free quiz matches you with fiduciary financial advisors in your area in 5 minutes. Each advisor is legally bound to act in your best interest.
If you're ready to acheive your financial goals, get started now.
pixel

ANP Insider Trading (Antisense Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Antisense Therapeutics Insider Trading History Chart

Antisense Therapeutics Share Price & Price History

A$0.00
+0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
This may be 2021's Hottest Ground Floor Story
This oil company is creating trust in the massive trillion dollar trading world
Find out why here

Antisense Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2020Robert MosesInsiderIssued90,201A$0.10A$9,020.10
12/23/2019Graham MitchellInsiderIssued7,000,000A$0.09A$609,000.00
12/20/2019Robert MosesInsiderBuy100,000A$0.09A$8,800.00
12/18/2019Graham MitchellInsiderExercise48,036A$0.08A$3,842.88
12/16/2019Robert MosesInsiderBuy618,888A$0.08A$49,511.04
12/3/2019Robert MosesInsiderBuy800,000A$0.08A$64,000.00
11/2/2018Mark DiamondInsiderBuy157,856A$0.04A$5,840.67
See Full Table
Antisense Therapeutics logo
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
Read More

Today's Range

Now: N/A

50 Day Range

MA: A$0.05
A$0.05
A$0.05

52 Week Range

Now: N/A

Volume

1,318,309 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Antisense Therapeutics?

Antisense Therapeutics' top insider shareholders include:
  1. Graham Mitchell (Insider)
  2. Robert Moses (Insider)
Live Streaming Stocks Explode
Lockdown fueled growth explodes live-streaming service.
Get the stock symbol here now